Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBREXIA-AF
NL-OMON60314Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of milvexian in Atrial fibrillation (AFib) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Composite of stroke and non-CNS systemic embolism. Started Sep 2023; status: active, not recruiting.
02
Drugs
milvexian
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON60314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60314.